Telix Appoints David Gill as Chair
Telix today announces that David Gill has been appointed Chair of the Board, effective immediately.
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Telix today announces its financial results for the period ended June 30, 2026.
Telix to Host R&D Day in New York City
Telix today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Telix H1 2026 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.
Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate, has been validated and accepted for review.
Notice of Annual General Meeting 2026
Telix announces its Annual General Meeting of shareholders to be held at
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer.
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies.
FDA Accepts NDA for TLX101-Px (Pixclara®)
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer), and has assigned a PDUFA goal date of September 11, 2026.